Heartbeat Bio develops advanced cardiac organoid screening platforms to accelerate cardiac drug discovery and development. The company utilizes multi-chamber heart organoids to model human heart development and disease states. This technology supports the identification of novel therapeutic targets for conditions like heart failure and inherited heart muscle disorders.
Funding
$11.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IAFounders
Product
Problem
Traditional cardiac drug discovery methods often rely on animal models or 2D cell cultures that fail to accurately replicate human heart physiology, leading to high failure rates in clinical trials. Existing in vitro models lack the structural complexity and cell-cell interactions necessary to mimic human heart development and disease. This results in inefficient screening processes and inaccurate prediction of drug efficacy and toxicity.
Solution
HeartBeat.bio offers a high-throughput 3D screening platform that utilizes human cardiac organoids, termed Cardioids, to improve the accuracy and efficiency of cardiac drug discovery. The platform guides induced pluripotent stem cells (iPSCs) to self-organize into beating, hollow, spherical chambers that mimic human heart development and physiology. These Cardioids replicate the native architecture of key cardiac cell types, maintaining a consistent, physiologically relevant beating pattern, providing a more predictive model for cardiac diseases. By integrating these cardiac models with specialized assays in an automated, industry-standard 384-well format, HeartBeat.bio delivers a scalable and cost-effective platform for advanced, disease-relevant drug testing and discovery. The platform also incorporates AI-powered analytics to provide deep, clinically relevant insights that accelerate and de-risk cardiac drug discovery.
Target Audience
The primary customers are pharmaceutical companies, biotech firms, and research institutions involved in cardiac drug discovery and development.
Features
- Generation of self-organizing Cardioids from iPSCs, replicating human heart chamber structure and function
- Customizable models for heart diseases, including myocardial fibrosis and genetic cardiomyopathies
- Comprehensive assay suite for characterizing heart disease phenotypes at structural, functional, and molecular levels
- Fully automated, industry-standard 384-well format for high-throughput screening
- AI-driven data analytics for predictive insights and target discovery
- Proprietary technology enabling precise control over cellular composition within the Cardioids
- Integrated quality control measures to ensure reproducibility and reliability of results